Table 4. Patient ACT 87524.

HLA	Epitope location	HXB2 epitope sequence (MHC IC50)	Sampling dates after primary infection (% of RT UDPS variants)
			3.5 months	10 months	10 months		34 months
			RNA	RNA	DNA	treatment	DNA
A*02:01	p17	SLYNTVATL	SLYNTVAVL	SLYNTVAVL	SLYNTVAVL		SLYNTVAVL
	(77–85)	(256.45)	(379.80)	(379.80)	(379.80)		(379.80)
	RT	ALVEICTEM	ALVEICTEM	ALVEICTEM	ALVEICTEM		ALVEICTEM
	(33–41)	(41.72)	(100%)	(100%)	(92%) (41.72)		(100%)
			(41.72)	(41.72)	VLVEICTEM		(41.72)
					(4%) (66.92)
					ALVKICTEI
					(4%) (109.35)
B*58:01	p24	TSTLQEQIGW	ND	TSNLQEQIGW	TS[NT]LQEQI[GA]W		TS[NT]LQEQI[GA]W
	(108–117)	(50.78)		(32.78)	(32.13 to 50.78)		(32.13 to 50.78)